Asia News

Found 44,693 articles

• Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma

  2/3/2023

  Gracell Biotechnologies Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared Gracell's Investigational New Drug (IND) application and the Company can proceed to initiate a Phase 1b/2 clinical trial in the U.S. of GC012F, an autologous CAR-T therapeutic candidate, for the treatment of relapsed/refractory multiple myeloma (RRMM).

• Dexlevo’s GOURI Symposium and Brand Event at IMCAS 2023

  2/3/2023

  Dexlevo, a company specializing in aesthetic medical devices, successfully held a symposium dedicated to its exclusive product, ‘GOURI’, at the IMCAS World Congress 2023 in Paris.

• Structure Therapeutics Announces Pricing of Upsized Initial Public Offering

  2/3/2023

  Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the pricing of its upsized initial public offering of 10,740,000 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $15.00 per ADS.

• Kyocera Develops New “Contactless Intelligent Millimeter-Wave Sensing System”

  2/2/2023

  Kyocera Corporation (President: Hideo Tanimoto) today announced it has developed a new “contactless intelligent millimeter-wave sensing system”.

• Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer

  2/2/2023

  Purple Biotech Ltd. today announced that it has entered into an agreement for the acquisition of Immunorizon Ltd., a private company developing potential multi-specific T and NK cell engager oncology therapies that selectively activate the immune response within the tumor microenvironment.

• Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of Wet AMD

  2/2/2023

  Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, announced that it has dosed the first patient in a clinical trial of its innovative gene therapy product, FT-003, at the Ophthalmology Hospital of Tianjin Medical University in Tianjin, China.

• Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3

  2/2/2023

  Takeda announced financial results for the third quarter of fiscal year 2022.

• SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan

  2/2/2023

  SONIRE Therapeutics Inc., based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of unresectable pancreatic cancer with SONIRE's next-generation High-Intensity Focused Ultrasound therapy system.

• BiondVax Presenting at BIO CEO & Investor Conference - February 02, 2023

  2/2/2023

  BiondVax Pharmaceuticals Ltd., a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced that its CEO Amir Reichman will present at the BIO CEO & Investor Conference.

• BriSTAR Immunotech to Present at the BIO CEO & Investor Conference

  2/2/2023

  BriSTAR Immunotech, a clinical-stage cell therapy company, announced today that its Chief Executive Officer, James Pan , Ph.D., will be presenting at the 25th BIO CEO & Investor Conference.

• Prenetics to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

  2/2/2023

  Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14 to February 16, 2023.

• Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development

  2/1/2023

  Jaguar Health, Inc. and SynWorld Technologies Corporation (SynWorld) today announced that the two companies have mutually agreed to terminate the exclusive license and services agreement executed in June 2022 for the treatment of diarrhea in dogs in the China market with Jaguar's Canalevia® (crofelemer delayed-release tablets) prescription drug product effective January 31, 2023.

• GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate

  2/1/2023

  GreenLight Biosciences today announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway. 

• HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update

  2/1/2023

  HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for 2022 and provided business updates.

• Record short videos to assess Parkinson's disease, NERVTEX's First-in-Class AI-based Movement Dysfunction Assessment Software medical device approved

  2/1/2023

  NERVTEX's MoDAS (Movement Dysfunction Assessment Software) system, which is a First-in-Class Artificial Intelligence/Machine Learning (AI/ML)- based Software as a Medical Device(SaMD) for the analysis of motor symptoms of Parkinson's disease and other movement disorders, has been approved by the China National Medical Products Administration, making it the first video-based AI-powered medical device for the assessment of movement disorders.

• Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program

  2/1/2023

  Cidara Therapeutics, Inc. and WuXi XDC announced an expansion of their existing collaboration under which WuXi XDC will provide investigational new drug -enabling chemistry, manufacturing and controls development services for Cidara’s CD73 oncology DFC program.

• Ronovo Surgical Emerges with $50M+ to Accelerate Paradigm Shift Towards Intelligent Robotic Laparoscopy

  2/1/2023

  One of the fastest growing companies in the global robotic and digital surgery space, Ronovo Surgical recently announced successful closing of new financing to accelerate its vision of broad, cross-specialty adoption of robotic-assisted surgery.

• Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers

  2/1/2023

  Sirnaomics Ltd. announced that it is advancing the clinical development of STP705 for the treatment of two non-melanoma skin cancers: Squamous Cell Carcinoma in situ and Basal Cell Carcinoma.

• BeiGene to Present at Upcoming Investor Conferences - February 1, 2023

  2/1/2023

  BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences.

• Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder

  1/31/2023

  BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced the publication of a comparative study of BrainsWay’s Deep Transcranial Stimulation H1 Coil, which targets the lateral prefrontal cortex, and the Company’s H7 Coil, which targets the medial prefrontal cortex.